BioGenCell’s patent-pending technology platform provides a comprehensive solution for most aspects of cellular therapy. It supports both rapid manufacturing and long-term storage (bio-banking) of therapeutic cellular products, which can be used to treat the patient (autologous) or other patients (allogeneous) in order to regenerate damaged tissues in diabetes, heart failure, stroke, blindness, cancer and a range of immunological diseases.

    BioGenCell’s platform, process and products provide numerous advantages over existing stem cell therapies:

  • A single administration is sufficient to achieve a long-lasting therapeutic effect
  • The stem-cell extraction process is quick, safe and cost-effective
  • Blood is obtained using routine collection methods (no anesthesia, surgery or drug pre-treatment)
  • No side effects or risk of immunological rejection are anticipated (as an autologous product)